Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat
- 1 March 2002
- journal article
- Published by Elsevier in Kidney International
- Vol. 61 (3), 939-950
- https://doi.org/10.1046/j.1523-1755.2002.00207.x
Abstract
No abstract availableKeywords
This publication has 52 references indexed in Scilit:
- Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities StudyKidney International, 2000
- Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal diseaseKidney International, 1999
- Amadorins: Novel Post-Amadori Inhibitors of Advanced Glycation ReactionsBiochemical and Biophysical Research Communications, 1999
- Immunochemical Evidence for Increased Formation of Advanced Glycation End Products and Inhibition by Aminoguanidine in Diabetic Rat LensesBiochemical and Biophysical Research Communications, 1997
- Vascular hypertrophy in experimental diabetes. Role of advanced glycation end products.Journal of Clinical Investigation, 1997
- Abnormal Lipid Metabolism and Renal Disorders.The Tohoku Journal of Experimental Medicine, 1997
- Functional Microcirculatory Impairment: A Possible Source of Reduced Skin Oxygen Tension in Human Diabetes MellitusMicrovascular Research, 1996
- Role of the Maillard Reaction in Diabetes Mellitus and Diseases of AgingDrugs & Aging, 1996
- The Advanced Glycation End Product, N∊-(Carboxymethyl)lysine, Is a Product of both Lipid Peroxidation and Glycoxidation ReactionsJournal of Biological Chemistry, 1996
- Thiamine Pyrophosphate and Pyridoxamine Inhibit the Formation of Antigenic Advanced Glycation End-Products: Comparison with AminoguanidineBiochemical and Biophysical Research Communications, 1996